September 3rd 2020 - Press notes
Arnau Busquets-García, an IMIM researcher, receives an ERC Starting Grant for scientific excellence.
July 9th 2020 - Press notes
Dr. Arnau Busquets, currently a Ramon y Cajal researcher in the IMIM's Integrated Pharmacology and Systems Neuroscience Research Group is one of the first authors of this work.
June 30th 2020 - Press notes
The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating.
May 28th 2020 - Press notes
The MINDUP project began in January 2020 to support SMEs in the mental health care of their workers. Now adapting to the COVID-19 pandemic and highlighting its usefulness in current circumstances.
May 25th 2020 - Press notes
The company Chemotargets -based in the Barcelona Science Park and a leader in in the global market as a provider of intelligence and drug design prediction platform- has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) to discovery and development of new oncological therapies that respond to important unmet medical needs.
4th May, 2020 - Press notes
This is the first time that anyone has studied how brain alterations at a functional level in mice with Down syndrome respond to chronic treatment with a component of green tea that we know, from other studies, improves executive functions in adults with Down syndrome.
February 6th 2020 - Press notes
The company, founded today, is backed by IMIM and UPF and is developing products and services based on the DisGeNET platform, one of the tools on the genetics of diseases with most information in the world.
23rd August, 2019 - Press notes
Preliminary results from a clinical trial led by the Hospital del Mar Medical Research Institute and Hospital del Mar show a good response to the drug in patients with metastatic tumours that did not respond to the usual treatment. It involves an inhibitor of a dual protein, mTORC1/2, which is key in tumour growth. The researchers had already demonstrated its effectiveness in in vitro and mouse models, in a study published in the journal Molecular Cancer Research.
10 July, 2019 - Press notes
Researchers from the Hospital del Mar Medical Research Institute have been able to prevent the growth of tumours and eliminate them using a treatment that combines chemotherapy with a protein inhibitor to prevent the repair of damaged DNA in cancer cells. The feasibility of this approach has been tested in mice, studying the evolution of metastatic colon tumours from human patients. The use of this drug combination will now be studied in human patients. The research has been published in the journal Molecular Cell.
28 June 2019 - Press notes
Study published in Cancer Immunology Research
Ageing of NK lymphocytes (Natural killer cells) in HER2-positive breast cancer patients can predict the success or failure of targeted treatments. A blood sample is sufficient for detecting this possible resistance biomarker that, if validated, will allow the therapy to be adapted when the disease is diagnosed. This is the first study to identify NK lymphocyte ageing as a parameter that may condition their anti-tumour potential.Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2025 Hospital del Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility
